39 citations
,
November 2015 in “Pediatric Nephrology” In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” This report describes a case of a 19-year-old woman experiencing severe recurrent angioedema with airway issues, leading to multiple emergency visits and unsuccessful treatment with typical steroid-sparing agents.
5 citations
,
June 2001 in “Annals of Internal Medicine” This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.
2 citations
,
December 2024 in “International Journal of Rheumatic Diseases” This study describes the first reported case of a 37-year-old woman developing alopecia universalis after switching from rituximab to ocrelizumab for progressive multiple sclerosis, suggesting that ocrelizumab may trigger autoimmune reactions in immunocompromised patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.